Search

Your search keyword '"Carcinoma -- Care and treatment"' showing total 1,171 results

Search Constraints

Start Over You searched for: Descriptor "Carcinoma -- Care and treatment" Remove constraint Descriptor: "Carcinoma -- Care and treatment"
1,171 results on '"Carcinoma -- Care and treatment"'

Search Results

1051. Diagnosis and treatment of thyroid carcinoma reviewed

1052. Diagnosis and treatment of thyroid carcinoma reviewed

1053. Diagnosis and treatment of thyroid carcinoma reviewed

1054. Platinum-based chemotherapy is efficacious in uterine papillary serous carcinoma

1055. Platinum-based chemotherapy is efficacious in uterine papillary serous carcinoma

1056. Platinum-based chemotherapy is efficacious in uterine papillary serous carcinoma

1057. Cases of small cell carcinoma of the esophagus analyzed

1058. Surgical treatment of salivary duct carcinoma of submandibular gland reviewed

1059. Surgical treatment of salivary duct carcinoma of submandibular gland reviewed

1060. Surgical treatment of salivary duct carcinoma of submandibular gland reviewed

1061. Combined therapies affected quality of life in nasopharyngeal carcinoma patients

1062. Combined therapies affected quality of life in nasopharyngeal carcinoma patients

1063. Combined therapies affected quality of life in nasopharyngeal carcinoma patients

1064. Use of chemoradiotherapy to treat esophageal carcinoma investigated

1065. Adjuvant systemic therapy used to treat male breast carcinoma

1066. Methods for enumerating circulating tumor cells in carcinoma patients compared

1067. Surgeon perspectives about local therapy for breast carcinoma shared

1068. Surgeon perspectives about local therapy for breast carcinoma shared

1069. Distribution of positive lymph nodes in patients with N0 oropharyngeal carcinoma assessed

1070. Surgeon perspectives about local therapy for breast carcinoma shared

1071. Gemcitabine and irinotecan treated patients with carcinoma of an unknown primary site

1072. Gemcitabine and irinotecan treated patients with carcinoma of an unknown primary site

1073. Gemcitabine and irinotecan treated patients with carcinoma of an unknown primary site

1074. Pharmacokinetics of S-1 plus cisplatin studied in patients with advanced gastric carcinoma

1075. Chemoradiotherapy improved tumor control of nasopharyngeal carcinoma

1076. Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome

1077. Pharmacokinetics of S-1 plus cisplatin studied in patients with advanced gastric carcinoma

1078. Chemoradiotherapy improved tumor control of nasopharyngeal carcinoma

1079. Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome

1080. Pharmacokinetics of S-1 plus cisplatin studied in patients with advanced gastric carcinoma

1081. Chemoradiotherapy improved tumor control of nasopharyngeal carcinoma

1082. Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome

1083. Adjuvant therapy with chemotherapy increases survival of women with serous carcinoma

1084. Adjuvant therapy with chemotherapy increases survival of women with serous carcinoma

1085. Adjuvant therapy with chemotherapy increases survival of women with serous carcinoma

1086. Exclusive low-dose-rate brachytherapy used to treat T2N0 mobile tongue carcinoma

1087. CT and FDG-PET image fusion impacted treatment planning and management of esophageal carcinoma

1088. Paclitaxel was well tolerated but showed limited efficacy in bronchioloalveolar carcinoma

1089. Exclusive low-dose-rate brachytherapy used to treat T2N0 mobile tongue carcinoma

1090. CT and FDG-PET image fusion impacted treatment planning and management of esophageal carcinoma

1091. Paclitaxel was well tolerated but showed limited efficacy in bronchioloalveolar carcinoma

1092. Exclusive low-dose-rate brachytherapy used to treat T2N0 mobile tongue carcinoma

1093. CT and FDG-PET image fusion impacted treatment planning and management of esophageal carcinoma

1094. Paclitaxel was well tolerated but showed limited efficacy in bronchioloalveolar carcinoma

1095. Low-dose GM-CSF used as salvage therapy in breast and genital tract carcinoma

1096. Brachytherapy is replacing other treatment modalities for prostate carcinoma

1097. Low-dose GM-CSF used as salvage therapy in breast and genital tract carcinoma

1098. Brachytherapy is replacing other treatment modalities for prostate carcinoma

1099. Low-dose GM-CSF used as salvage therapy in breast and genital tract carcinoma

1100. Brachytherapy is replacing other treatment modalities for prostate carcinoma

Catalog

Books, media, physical & digital resources